vs
CALERES INC（CAL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
CALERES INC的季度营收约是Revvity的1.0倍（$790.1M vs $772.1M），Revvity净利率更高（12.7% vs 0.3%，领先12.4%），CALERES INC同比增速更快（6.6% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-12.4M），过去两年Revvity的营收复合增速更高（9.0% vs 6.5%）
Caleres Inc是一家美国鞋履企业，旗下拥有并运营多个鞋履品牌，总部坐落于圣路易斯郊区密苏里州克莱顿。该企业前身是1878年在圣路易斯成立的Bryan, Brown & Company，此后历经多次更名，其前身汉密尔顿-布朗鞋业在20世纪初曾是美国最大的鞋履制造商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CAL vs RVTY — 直观对比
营收规模更大
CAL
是对方的1.0倍
$772.1M
营收增速更快
CAL
高出0.8%
5.9%
净利率更高
RVTY
高出12.4%
0.3%
自由现金流更多
RVTY
多$174.2M
$-12.4M
两年增速更快
RVTY
近两年复合增速
6.5%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $790.1M | $772.1M |
| 净利润 | $2.4M | $98.4M |
| 毛利率 | 41.8% | — |
| 营业利润率 | 1.5% | 14.5% |
| 净利率 | 0.3% | 12.7% |
| 营收同比 | 6.6% | 5.9% |
| 净利润同比 | -94.2% | 3.9% |
| 每股收益（稀释后） | $0.07 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CALRVTY
| Q4 25 | $790.1M | $772.1M | ||
| Q3 25 | $658.5M | $698.9M | ||
| Q2 25 | $614.2M | $720.3M | ||
| Q1 25 | $639.2M | $664.8M | ||
| Q4 24 | $740.9M | $729.4M | ||
| Q3 24 | $683.3M | $684.0M | ||
| Q2 24 | $659.2M | $691.7M | ||
| Q1 24 | $697.1M | $649.9M |
净利润CALRVTY
| Q4 25 | $2.4M | $98.4M | ||
| Q3 25 | $6.7M | $46.7M | ||
| Q2 25 | $6.9M | $53.9M | ||
| Q1 25 | $4.9M | $42.2M | ||
| Q4 24 | $41.4M | $94.6M | ||
| Q3 24 | $30.0M | $94.4M | ||
| Q2 24 | $30.9M | $55.4M | ||
| Q1 24 | $55.7M | $26.0M |
毛利率CALRVTY
| Q4 25 | 41.8% | — | ||
| Q3 25 | 43.4% | 53.6% | ||
| Q2 25 | 45.4% | 54.5% | ||
| Q1 25 | 43.0% | 56.5% | ||
| Q4 24 | 44.1% | — | ||
| Q3 24 | 45.5% | 56.3% | ||
| Q2 24 | 46.9% | 55.7% | ||
| Q1 24 | 43.9% | 54.6% |
营业利润率CALRVTY
| Q4 25 | 1.5% | 14.5% | ||
| Q3 25 | 1.4% | 11.7% | ||
| Q2 25 | 1.9% | 12.6% | ||
| Q1 25 | 1.2% | 10.9% | ||
| Q4 24 | 7.7% | 16.3% | ||
| Q3 24 | 6.2% | 14.3% | ||
| Q2 24 | 6.5% | 12.4% | ||
| Q1 24 | 4.4% | 6.8% |
净利率CALRVTY
| Q4 25 | 0.3% | 12.7% | ||
| Q3 25 | 1.0% | 6.7% | ||
| Q2 25 | 1.1% | 7.5% | ||
| Q1 25 | 0.8% | 6.4% | ||
| Q4 24 | 5.6% | 13.0% | ||
| Q3 24 | 4.4% | 13.8% | ||
| Q2 24 | 4.7% | 8.0% | ||
| Q1 24 | 8.0% | 4.0% |
每股收益（稀释后）CALRVTY
| Q4 25 | $0.07 | $0.86 | ||
| Q3 25 | $0.20 | $0.40 | ||
| Q2 25 | $0.21 | $0.46 | ||
| Q1 25 | $0.17 | $0.35 | ||
| Q4 24 | $1.19 | $0.77 | ||
| Q3 24 | $0.85 | $0.77 | ||
| Q2 24 | $0.88 | $0.45 | ||
| Q1 24 | $1.56 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $616.8M | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CALRVTY
| Q4 25 | $34.0M | $919.9M | ||
| Q3 25 | $191.5M | $931.4M | ||
| Q2 25 | $33.1M | $991.8M | ||
| Q1 25 | $29.6M | $1.1B | ||
| Q4 24 | $33.7M | $1.2B | ||
| Q3 24 | $51.8M | $1.2B | ||
| Q2 24 | $30.7M | $2.0B | ||
| Q1 24 | $21.4M | $1.7B |
股东权益CALRVTY
| Q4 25 | $616.8M | $7.3B | ||
| Q3 25 | $613.3M | $7.4B | ||
| Q2 25 | $605.2M | $7.6B | ||
| Q1 25 | $599.0M | $7.6B | ||
| Q4 24 | $598.3M | $7.7B | ||
| Q3 24 | $606.1M | $7.9B | ||
| Q2 24 | $570.3M | $7.9B | ||
| Q1 24 | $560.6M | $7.8B |
总资产CALRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $1.9B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $2.0B | $12.4B | ||
| Q3 24 | $2.0B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B | ||
| Q1 24 | $1.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-12.4M | $161.8M |
| 自由现金流率自由现金流/营收 | -1.6% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | -0.50× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $14.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CALRVTY
| Q4 25 | $-1.2M | $182.0M | ||
| Q3 25 | $47.3M | $138.5M | ||
| Q2 25 | $-5.7M | $134.3M | ||
| Q1 25 | $28.7M | $128.2M | ||
| Q4 24 | $-39.8M | $174.2M | ||
| Q3 24 | $79.6M | $147.9M | ||
| Q2 24 | $36.1M | $158.6M | ||
| Q1 24 | $43.0M | $147.6M |
自由现金流CALRVTY
| Q4 25 | $-12.4M | $161.8M | ||
| Q3 25 | $35.0M | $120.0M | ||
| Q2 25 | $-26.2M | $115.5M | ||
| Q1 25 | $18.0M | $112.2M | ||
| Q4 24 | $-57.4M | $149.8M | ||
| Q3 24 | $68.5M | $125.6M | ||
| Q2 24 | $26.3M | $136.6M | ||
| Q1 24 | $32.4M | $129.7M |
自由现金流率CALRVTY
| Q4 25 | -1.6% | 21.0% | ||
| Q3 25 | 5.3% | 17.2% | ||
| Q2 25 | -4.3% | 16.0% | ||
| Q1 25 | 2.8% | 16.9% | ||
| Q4 24 | -7.7% | 20.5% | ||
| Q3 24 | 10.0% | 18.4% | ||
| Q2 24 | 4.0% | 19.7% | ||
| Q1 24 | 4.6% | 20.0% |
资本支出强度CALRVTY
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 3.3% | 2.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 2.4% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 1.5% | 3.2% | ||
| Q1 24 | 1.5% | 2.7% |
现金转化率CALRVTY
| Q4 25 | -0.50× | 1.85× | ||
| Q3 25 | 7.05× | 2.97× | ||
| Q2 25 | -0.81× | 2.49× | ||
| Q1 25 | 5.82× | 3.03× | ||
| Q4 24 | -0.96× | 1.84× | ||
| Q3 24 | 2.66× | 1.57× | ||
| Q2 24 | 1.17× | 2.87× | ||
| Q1 24 | 0.77× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAL
| Brand Portfolio | $383.7M | 49% |
| Landed Wholesale | $148.1M | 19% |
| Wholesale E Commerce | $75.0M | 9% |
| Ecommerce | $68.8M | 9% |
| Stuart Weitzman Brand | $45.8M | 6% |
| Landed Wholesale Ecommerce Drop Ship | $30.6M | 4% |
| First Cost Wholesale | $14.9M | 2% |
| Clt Brand Solutions | $10.2M | 1% |
| License And Royalty | $2.1M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
